U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

At the outset of the meeting, the FDA's new top vaccine regulator, Vinay Prasad, said he and FDA leaders wanted to "give people a little more time to digest the policy." He said that the FDA is still ...

Point-of-care medication dispensing offers a return to a more straightforward approach, common to physician practices ...

Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...

Some members of the Vaccines and Related Biologics Products Advisory Committee worried that a strain change would require new ...

A group of experts who advise the US Food and Drug Administration on its vaccine decisions voted unanimously Thursday to make ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer ( PFE 2.20%) and Medical Properties Trust ( MPW -0.10%).

Since President Donald J. Trump took office a second time on Jan. 20, leaders across the biotechnology and pharmaceutical ...

U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...